{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:09:09Z","timestamp":1761919749225,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.respe.2013.08.001","type":"journal-article","created":{"date-parts":[[2013,11,7]],"date-time":"2013-11-07T09:46:16Z","timestamp":1383817576000},"page":"539-544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diff\u00e9rences de taux de substitution des m\u00e9dicaments g\u00e9n\u00e9riques en Midi-Pyr\u00e9n\u00e9es en fonction des classes pharmaco-th\u00e9rapeutiques"],"prefix":"10.1016","volume":"61","author":[{"given":"A.","family":"Sommet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Georgel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-C.","family":"Poutrain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Oustric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bourrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-L.","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Birebent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2009","series-title":"Perception du m\u00e9dicament g\u00e9n\u00e9rique dix ans apr\u00e8s le droit de substitution\u00a0: enqu\u00eate aupr\u00e8s de pharmaciens d\u2019officine et patients en Haute-Garonne","author":"Ostan","key":"10.1016\/j.respe.2013.08.001_bib0005"},{"key":"10.1016\/j.respe.2013.08.001_bib0010","first-page":"99","article-title":"D\u00e9finition des m\u00e9dicaments g\u00e9n\u00e9riques entre enjeux th\u00e9rapeutiques et \u00e9conomiques. L\u2019exemple du march\u00e9 fran\u00e7ais des inhibiteurs de la pompe \u00e0 protons","volume":"3\u20134","author":"Nouguez","year":"2007","journal-title":"Rev Fr Affaires Soc"},{"key":"10.1016\/j.respe.2013.08.001_bib0015","first-page":"21","article-title":"G\u00e9n\u00e9rique des anti\u00e9pileptiques\u00a0: la diff\u00e9rence par rapport au princeps\u00a0: OUI, mais attention aux cumuls des diff\u00e9rences entre g\u00e9n\u00e9riques\u00a0!","volume":"18","author":"Despas","year":"2011","journal-title":"Bull Info Pharmacol"},{"key":"10.1016\/j.respe.2013.08.001_bib0020","first-page":"9","article-title":"G\u00e9n\u00e9riques, \u00e9quivalents th\u00e9rapeutiques, copies, princeps\u00a0: similitudes et diff\u00e9rences","volume":"126","author":"Bagheri","year":"2007","journal-title":"Genesis"},{"key":"10.1016\/j.respe.2013.08.001_bib0025","first-page":"76","article-title":"Les m\u00e9dicaments g\u00e9n\u00e9riques","volume":"124","author":"Jeanjean","year":"2005","journal-title":"Louvain Med"},{"key":"10.1016\/j.respe.2013.08.001_bib0030","doi-asserted-by":"crossref","unstructured":"Menk\u00e8s CJ. Place des g\u00e9n\u00e9riques dans la prescription. Rapport de l\u2019Acad\u00e9mie Nationale de M\u00e9decine. 2012.","DOI":"10.1016\/S0001-4079(19)31843-6"},{"key":"10.1016\/j.respe.2013.08.001_bib0035","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1345\/aph.1M141","article-title":"Comparing generic and innovator drugs: a review of 12years of bioequivalence data from the United States Food and Drug Administration","volume":"43","author":"Davit","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.respe.2013.08.001_bib0040","unstructured":"Morisson J. G\u00e9n\u00e9riques. La qualit\u00e9 en question\u00a0? www.pharmaceutique.com. 2009."},{"key":"10.1016\/j.respe.2013.08.001_bib0045","article-title":"Texte de la nouvelle convention m\u00e9dicale des m\u00e9decins g\u00e9n\u00e9ralistes et des m\u00e9decins sp\u00e9cialistes, art. 26.2. Arr\u00eat\u00e9 du 22 septembre 2011 portant approbation de la convention nationale des m\u00e9decins g\u00e9n\u00e9ralistes et sp\u00e9cialistes","author":"Anonyme","year":"2011","journal-title":"J Officiel Republique Fr"},{"key":"10.1016\/j.respe.2013.08.001_bib0050","first-page":"6","article-title":"Utilisation des m\u00e9dicaments g\u00e9n\u00e9riques des anti\u00e9pileptiques en France\u00a0: r\u00e9sultats d\u2019une enqu\u00eate aupr\u00e8s des neurologues et revue de la litt\u00e9rature","volume":"19","author":"Biraben","year":"2007","journal-title":"Epilepsies"},{"key":"10.1016\/j.respe.2013.08.001_bib0055","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1755-5949.2010.00210.x","article-title":"Switching from brand-name to generic psychotropic medications: a literature review","volume":"17","author":"Desmarais","year":"2011","journal-title":"CNS Neurosci Therapeut"},{"key":"10.1016\/j.respe.2013.08.001_bib0060","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/01.nrl.0000340793.61037.09","article-title":"Risks and benefits of generic antiepileptic drugs","volume":"14","author":"G\u00f3mez-Alonso","year":"2008","journal-title":"Neurologist"},{"key":"10.1016\/j.respe.2013.08.001_bib0065","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/j.1875-9114.2012.01099.x","article-title":"Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review","volume":"32","author":"Talati","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.respe.2013.08.001_bib0070","unstructured":"Anonyme. Recommandations sur la substitution des m\u00e9dicaments anti\u00e9pileptiques dans l\u2019\u00e9pilepsie. Lettre de l\u2019AFSSAPS aux professionnels de sant\u00e9. 2008."},{"key":"10.1016\/j.respe.2013.08.001_bib0075","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ana.22452","article-title":"Assessing bioequivalence of generic antiepilepsy drugs","volume":"70","author":"Krauss","year":"2011","journal-title":"Ann Neurol."},{"key":"10.1016\/j.respe.2013.08.001_bib0080","first-page":"260","article-title":"Remplacement d\u2019une sp\u00e9cialit\u00e9 \u00e0 base de levothyroxine par une autre\u00a0: pr\u00e9cautions \u00e0 prendre","volume":"31","author":"Anonyme","year":"2011","journal-title":"Rev Prescrire"},{"key":"10.1016\/j.respe.2013.08.001_bib0085","unstructured":"Anonyme. Commission d\u2019autorisation de mise sur le march\u00e9 des m\u00e9dicaments - R\u00e9union no\u00a0481. www.afssaps.fr. 2010."},{"key":"10.1016\/j.respe.2013.08.001_bib0090","unstructured":"Anonyme. AFSSAPS-Lettre aux professionnels de sant\u00e9-Recommandations sur la substitution des sp\u00e9cialit\u00e9s \u00e0 base de l\u00e9vothyroxine sodique. www.ameli.fr. 2010."},{"key":"10.1016\/j.respe.2013.08.001_bib0095","unstructured":"Anonyme. Point d\u2019information. D\u00e9penses de m\u00e9dicaments\u00a0: une croissance ma\u00eetris\u00e9e en 2010. www.ameli.fr.2011."},{"key":"10.1016\/j.respe.2013.08.001_bib0100","unstructured":"Anonyme.Rapport ANSM. Les m\u00e9dicaments g\u00e9n\u00e9riques\u00a0: des m\u00e9dicaments \u00e0 part enti\u00e8re. 2012. http:\/\/www.medicamentsgeneriques.info\/wp-content\/uploads\/2009\/12\/Ansm_Rapport-Generiques_Decembre2012.pdf."}],"container-title":["Revue d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S039876201301047X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S039876201301047X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:36:32Z","timestamp":1759970192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S039876201301047X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S039876201301047X"],"URL":"https:\/\/doi.org\/10.1016\/j.respe.2013.08.001","relation":{},"ISSN":["0398-7620"],"issn-type":[{"type":"print","value":"0398-7620"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diff\u00e9rences de taux de substitution des m\u00e9dicaments g\u00e9n\u00e9riques en Midi-Pyr\u00e9n\u00e9es en fonction des classes pharmaco-th\u00e9rapeutiques","name":"articletitle","label":"Article Title"},{"value":"Revue d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.respe.2013.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}